Latest News

Supporting Patients With AD and Their Caregivers: Insights from Argentina
Supporting Patients With AD and Their Caregivers: Insights from Argentina

May 2nd 2024

Eli Lilly Resubmits BLA for Lebrikizumab for the Treatment of Moderate to Severe AD
Eli Lilly Resubmits BLA for Lebrikizumab for the Treatment of Moderate to Severe AD

April 30th 2024

Upadacitinib Outperforms Dupilumab in Primary and Secondary End Points in Head-to-Head AD Study
Upadacitinib Outperforms Dupilumab in Primary and Secondary End Points in Head-to-Head AD Study

April 25th 2024

© 2024 MJH Life Sciences

All rights reserved.